These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 16965583)
1. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Fast LD; DiLeone G; Cardarelli G; Li J; Goodrich R Transfusion; 2006 Sep; 46(9):1553-60. PubMed ID: 16965583 [TBL] [Abstract][Full Text] [Related]
2. Functional inactivation of white blood cells by Mirasol treatment. Fast LD; Dileone G; Li J; Goodrich R Transfusion; 2006 Apr; 46(4):642-8. PubMed ID: 16584442 [TBL] [Abstract][Full Text] [Related]
3. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688 [TBL] [Abstract][Full Text] [Related]
4. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Picker SM; Steisel A; Gathof BS Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255 [TBL] [Abstract][Full Text] [Related]
5. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Marschner S; Fast LD; Baldwin WM; Slichter SJ; Goodrich RP Transfusion; 2010 Nov; 50(11):2489-98. PubMed ID: 20529002 [TBL] [Abstract][Full Text] [Related]
6. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Fast LD; Nevola M; Tavares J; Reddy HL; Goodrich RP; Marschner S Transfusion; 2013 Feb; 53(2):373-81. PubMed ID: 22612327 [TBL] [Abstract][Full Text] [Related]
7. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874 [TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
9. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products. Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832 [TBL] [Abstract][Full Text] [Related]
10. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989 [TBL] [Abstract][Full Text] [Related]
11. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study. Picker SM; Steisel A; Gathof BS Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791 [TBL] [Abstract][Full Text] [Related]
13. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Cardo LJ; Rentas FJ; Ketchum L; Salata J; Harman R; Melvin W; Weina PJ; Mendez J; Reddy H; Goodrich R Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665 [TBL] [Abstract][Full Text] [Related]
14. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Ambruso DR; Thurman G; Marschner S; Goodrich RP Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996 [TBL] [Abstract][Full Text] [Related]
16. Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System. Lachert E; Woźniak J; Antoniewicz-Papis J; Krzywdzińska A; Kubis J; Mikołowska A; Letowska M Adv Clin Exp Med; 2017; 26(1):7-13. PubMed ID: 28397426 [TBL] [Abstract][Full Text] [Related]
17. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
18. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Fast LD; DiLeone G; Marschner S Transfusion; 2011 Jul; 51(7):1397-404. PubMed ID: 21155832 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990 [TBL] [Abstract][Full Text] [Related]
20. [Study of graft-versus -leukemia activity of gamma-ray irradiated haplomismatched donor lymphocytes infusion]. Zhang L; Guo K; Dong B; Luo Q Zhonghua Xue Ye Xue Za Zhi; 2000 Feb; 21(2):81-3. PubMed ID: 11876964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]